why choose us

First received: July 01, 2022

Clinical Trial: Glecaprevir/Pibrentasvir for the Treatment of PTSD

Study Status: Completed

Recruit Status: RECRUITING

Condition: PTSD

Study Type: INTERVENTIONAL


Official Title: Glecaprevir/Pibrentasvir for the Treatment of PTSD

Brief Summary: An open-label pilot study to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).

Read more